Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data
Open Access
- 14 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 60 (11), 1475-1486
- https://doi.org/10.1007/s40262-021-01029-7
Abstract
Introduction Vortioxetine is an antidepressant primarily metabolized by the polymorphic enzyme cytochrome P450 (CYP) 2D6. A population pharmacokinetic (popPK) model of vortioxetine and its CYP2D6-dependent metabolite was recently published. Objective The aim of the current study was to assess the predictive performance of the popPK model using vortioxetine concentration measurements from a clinical setting. Furthermore, the study aimed to evaluate the ability of different CYP2D6 phenotype classification systems to provide accurate concentration predictions. Methods Overall, 1388 patients receiving vortioxetine treatment were identified from a therapeutic drug monitoring (TDM) database in Oslo, Norway; 334 CYP2D6-genotyped patients with 502 serum concentrations of vortioxetine, analysed by a validated ultra-high-performance liquid chromatography–high-resolution mass spectrometry (UHPLC-HRMS) method, were retrospectively included. The performance of the vortioxetine popPK model was tested on the clinical data from the TDM database. Results Overall, the model had a good ability to predict vortioxetine concentrations measured in clinical practice, with a slight tendency to overpredict concentrations. Using simulation-based diagnostics, 76% of the prediction-corrected TDM concentrations were within the 90% prediction interval based on 1000 simulated data sets. Prediction-based diagnostics showed the best performance for CYP2D6 poor and ultrarapid metabolizers, with a median prediction error (MDPE) of 12% and 23%, respectively, while the poorest performance was observed for normal metabolizers, with an MDPE of 66%. In the comparison of different CYP2D6 phenotype classification systems, the use of differentiated activity scores for decreased function alleles did not improve the concentration predictions. Grouping the CYP2D6 genotypes into the four conventional phenotype groups provided predictions closest to the TDM measured concentrations. Conclusion TDM data provide a unique insight into real-world clinical practice with vortioxetine. The tendency of the popPK model to overpredict vortioxetine concentrations measured in TDM may be attributed to several factors, including poor treatment compliance for some patients and, to a lesser extent, lack of information on patient characteristics and misspecified CYP2D6 alleles. To optimize personalized therapy with vortioxetine, real-world clinical data sets originating from different ethnicities need to be studied in the future.Funding Information
- Innovationsfonden (8053-00083B)
This publication has 19 references indexed in Scilit:
- A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adultsEuropean Neuropsychopharmacology, 2016
- The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studiesJournal of Psychopharmacology, 2016
- Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing GenotypeTherapeutic Drug Monitoring, 2016
- Population Pharmacokinetic Meta‐Analysis of Vortioxetine in Healthy IndividualsBasic & Clinical Pharmacology & Toxicology, 2014
- Complexities ofCYP2D6gene analysis and interpretationInternational Review of Psychiatry, 2013
- Identification of the Cytochrome P450 and Other Enzymes Involved in the In Vitro Oxidative Metabolism of a Novel Antidepressant, Lu AA21004Drug Metabolism and Disposition, 2012
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of PhenotypeClinical Pharmacology & Therapeutics, 2007
- Depression Is a Risk Factor for Noncompliance With Medical TreatmentArchives of Internal Medicine, 2000
- Population PharmacokineticsClinical Pharmacokinetics, 1986